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Abstract
Background—Reduced low forced expiratory volume in 1 second (FEV1) is reportedly
associated with an increased risk of atrial fibrillation (AF). Extant reports do not provide separate
estimates for never smokers, and for African Americans, who incongruously have lower AF
incidence than Caucasians.
Methods and Results—We examined 15,004 middle-aged African Americans and Caucasians
enrolled in ARIC cohort study. Standardized spirometry were collected at the baseline
examination. Incident AF was identified from the first among the following: ICD codes for AF on
hospital discharge records or death certificates or 12-lead ECGs performed during three triennial
follow-up visits. Over an average follow-up of 17.5 years, a total of 1,691 (11%) participants
developed new onset AF. The rate of incident AF was inversely associated with FEV1 in each of
the four race and gender- groups. After multivariable adjustment for traditional cardiovascular
disease risk factors and height, hazard ratios (95% confidence intervals) of AF comparing the
lowest with the highest quartile of FEV1 were 1.37 (1.02,1.83) for white women, 1.49 (1.16,1.91)
for white men, 1.63 (1.00,2.66) for black women, and 2.36 (1.30,4.29) for black men. The above
associations were observed across all smoking status categories. Moderate/severe airflow
obstruction (FEV1/FVC<0.70 and FEV1< 80% of predicted value) was also associated with higher
AF incidence.
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Conclusions—In this large population-based study with a long term follow-up, reduced FEV1
and obstructive respiratory disease were inversely - associated with a higher AF incidence after
adjusting for measured confounders.
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Introduction
Atrial fibrillation (AF), a common arrhythmia, is associated with higher risk of stroke, heart
failure (HF), dementia, and mortality 1, 2. Though borderline or elevated traditional risk
factors can explain more than half of the attributable risk of AF 3, studies examining non-
traditional risk factors or subclinical disease are limited 4.
AF and chronic obstructive pulmonary disease (COPD), defined by persistent airflow
obstruction on spirometry, frequently coexist in clinical settings. Poor lung function, namely
low Forced Expiratory Volume in 1 second (FEV1), and airflow obstruction, are associated
with increased risk factors predictive of AF such as coronary heart disease (CHD) 5 and
HF 6, and also with stroke, a common complication of AF 7, 8. Thus, poor lung function and
airflow obstruction may potentially lead to an increased risk of AF. However, few studies
have examined the association of lung function measures and airflow obstruction with
AF9–12. Given the potentially strong confounding by smoking, an assessment of such
associations among never smokers is particularly important. Lastly, since most studies on
the epidemiology of AF were conducted on Caucasians, studies are needed to fill in
knowledge gaps about AF in African Americans (AA), a group with paradoxically lower AF
incidence despite higher burden of other risk factors 13. Therefore, we examined whether
reduced lung function, as assessed by lower FEV1, or airflow obstruction assessed by
clinical history as well as airflow obstruction detected by spirometry were associated with a
higher incidence of AF in the Atherosclerosis Risk in Communities (ARIC) Study, a
predominantly biracial cohort of over 15,000 men and women from four US communities.
We also explored this association by race, gender, and smoking status.
Method
Study Population
The Atherosclerosis Risk in Communities (ARIC) study is a multi-center population-based
prospective study of risk factors for atherosclerosis and the burden of cardiovascular disease.
From 1987–1989, 15,792 adults (55.2% women) aged 45–64 years and from four U.S.
communities were enrolled, and completed a home interview and clinic visit. Participants
were from the following areas: Washington County, Maryland; suburbs of Minneapolis,
MN; Jackson, MS; and Forsyth County, North Carolina 14. Area probability sampling was
used at two sites with oversampling of African American at Forsyth County and exclusively
African Americans from Jackson. Three follow-up examination visits were conducted, each
approximately 3 years apart (the last ending in 1998). In addition, participants received
annual follow-up calls since the first visit inquiring about their health and hospitalizations.
Details of the ARIC study design have been published 14. The ARIC study was approved by
institutional review boards at each participating center, and written informed consent was
obtained from all participants.
In the present study, we excluded the participants who met any of the following hierarchical
criteria based on the baseline study visit: a) missing or non-readable ECGs (n=85), or
unknown prevalent AF status (n=225); b) prevalent AF or atrial flutter (n=37); c) missing
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(n=104) or implausible (n=12) data on lung function value; d) race/ethnicity other than
African Americans or Caucasians (n=47); e) missing information on important covariates,
including sitting height (n=15), cigarette smoke status (n=14), and cigarette-years of
smoking (n=249). After these exclusions, a total of 15,004 of participants (95% of original
study cohort) remained for analysis.
Assessment of Atrial Fibrillation
Electrocardiograms (ECGs) and a 2 two-minute rhythm strip from the first visit were
examined to identify participants with prevalent AF or atrial flutter. Details for the
assessment of AF have been reported previously15. AF events were identified from: 1)
ECGs performed during follow-up exams; 2) death certificates (ICD-9 code 437.3 or
ICD-10 code I48) 16; 3) hospital discharge records or death certificates through the end of
follow up through 2008.
Hospitalizations in ARIC participants were identified through annual follow-up calls and
review of local hospital discharges through 2008 17. An AF diagnosis was assigned if AF
was listed as any cause of death (ICD-9 427.3 or ICD-10 148). AF events identified during
hospitalization for cardiac surgery were excluded as these may not relate to the natural
history of AF and persistent will be capture in subsequent hospitalization. The validity of
hospital discharge diagnoses for AF reported 84% sensitivity and 98% specificity in the
ascertainment of AF event among ARIC cohort15. The date of incident AF was defined as
the first date when ECGs showed AF, hospital discharge coded as AF or death date when
AF was listed as a cause of death, whichever occurred first. Most AF incidence cases
(87.4%) were identified through hospital discharge codes only. Supplemental Table 1 shows
the distribution of AF cases according to the different sources of endpoint ascertainment.
Assessment of Pulmonary function
The main measures of lung function were FEV1, the volume of gas exhaled in the first
second of expiration; and forced vital capacity (FVC), the average maximal volume of gas
exhaled after maximal inspiratory effort. Spirometry was conducted at baseline using a
water-sealed Collins Survey II volume displacement spirometer (Collins Medical, Inc.) and
Pulmo-Screen II software (PDS Healthcare Products, 496 Inc.). At least three acceptable
spirograms were obtained from a minimum of five forced expirations. The best single
spirograms was identified by a computer and confirmed by a technician. Quality control was
carefully conducted throughout the study 18. All procedures followed the American Thoracic
Society guidelines 19.
Assessment of respiratory symptoms was based on self-responses to a standardized
questionnaire adapted from the Epidemiology Standardization Project 20. Airflow
obstruction was defined through two means either, a). Self-report of a physician diagnosis of
emphysema, bronchitis, or asthma, or b). Spirometry. Post-bronchodilator measurements are
required to define COPD optimally, but only pre-bronchodilator measurements were
available in this study. Airflow obstruction by spirometry was defined as FEV1/FVC<0.70.
We further classified those with airflow obstruction by spirometry into mild (FEV1≥ 80% of
predicted value) and moderate plus severe (FEV1< 80% of predicted value) per Global
Obstructive Lung Disease (GOLD) criteria21. Details of the airflow obstruction assessment
in ARIC study have been published 22.
Assessment of Covariates
For the present analysis, we used covariates measured at the first field center visit (1987–
89). Anthropometric measures were obtained by trained, certified study personnel following
a standardized protocol. Interviewers collected information on age, ethnicity, gender,
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smoking, highest education level, medical history, and other factors. For smoking history,
participants identified themselves as current, former or never smokers. The average number
of cigarette per day and number of years of smoking reported were multiplied to derive
cigarette-years of smoking. Education level was classified as did not complete high school
(≤ 11 years), high school diploma (12 years), and at least some college (>12 years). Body
mass index (BMI) was calculated from measurements of weight to the nearest pound and
height to the nearest centimeter, with the participants standing in a scrub suit and without
shoes. Sitting height was measured by having the participant sit on a stool approximately 32
inches high in a standard position. Actual sitting height was calculated as the seated
participant’s height minus the stool height. All sitting height measurements were recorded to
the centimeter, rounding down. Participants were asked to bring their current medications at
this visit. A medication use history was obtained by self-report of medication intake during
last two weeks and by reviewing medication brought by participants to their visit. Each
medication was coded by trained and certified interviewers with the use of a computerized
medication classification system. Use of medications such as adrenergic beta-agonists,
xanthine, and anti-cholinergics was examined as potential confounders. At baseline,
inflammatory markers such as white cell count, hemostatic markers such as plasma
fibrinogenprotein C, and von Willebrand factor, acute phase and nutrition marker such as
albumin, and plasma lipid levels, were measured in central laboratories and using
standardized and validated methods as previously described 23. Prevalent CHD was defined
as self-reported physician-diagnosed CHD or the presence of a previous myocardial
infarction by ECGs, or self-reported history of coronary bypass or angioplasty of the
coronary arteries. Prevalent HF was identified as presence of HF according to Gothenburg
criteria 24 or self-reported HF medication use in the past 2 weeks.
Statistical Analysis
FEV1 and FVC vary widely by race and gender, and so does AF rates. Thus, all analyses
used either race and gender specific FEV1 groupings or were done separately by race and
gender. Initially, we explored the association between measures of lung function and
incident AF using restricted cubic spline (Figure 1) 25. The restricted splines show that the
relative HRs decrease sharply as the FEV1 and FVC were under 2.1 liters for FEV1 (3.0 for
FVC), but was equivalent beyond 3.5 liters for FEV1 (4.6 for FVC), indicating inflection at
those values. Thus, there was a threshold effect around median with most risk seen in the
lowest quartile. Based on the shape of splines and to be conservative, FEV1 and FVC were
categorized into race/gender specific quartiles. The median values in each quartile were used
as continuous variables for trend estimation. A one standard deviations (SD) difference
(race- and gender- specific SD) in the spirometry value was also used for trend estimate.
Cox proportional hazards regression models were used to estimate the hazard ratios (HRs)
and 95% confidence intervals (CI) of AF by quartiles of FEV1 and FVC using the highest
quartile as reference. Each participant contributed follow-up time from the date of the
baseline examination until the earliest of the following dates: AF event, death, lost to
follow-up or administrative censoring on 31st December 2008. All models were run by
gender-race groups and were adjusted for age, sitting height, and sitting height2 instead of
using % predicted measures which may violate the homogeneity of variance assumptions 26.
The following additional analyses were performed: a) stratified analyses by smoking status
(never, former, and current) given its strong potential confounding effect, while adjusting for
pack-years of smoking to reduce residual confounding in current or former smokers; b)
additional adjustment for obesity (BMI) and pro-inflammatory markers (including white
blood cell count, fibrinogen level, albumin level, protein C, and von Willebrand factor) ; c)
analyses after excluding those with (or missing information on) HF or CHD, and both to
remove potential for confounding due to these conditions; d) analyses after excluding those
Li et al. Page 4













without airflow obstruction to remove potential for ascertainment bias; and d) further
adjustment for bronchodilators using (beta-agonist, xanthines, and anticholinergic). All
analyses were conducted using SAS of version 9.2 (SAS Institute Inc., Cary, North
Carolina). A two sided p value of <0.05 for main effects and <0.2 for interactions was
considered statistically significant.
Results
A total of 15,004 participants (55.1% female, 26.2% African Americans, average (SD) age
at baseline 54 (6) years) were followed for an average of 17.5 (interquartile range 16.6 –
20.6) years. A total of 1,691 (11.3%) participants developed new-onset AF. The selected
baseline characteristics of all participants by race- and gender- specific quartiles of FEV1 are
shown in Table 1. In general, having lower FEV1 was associated with older age, shorter
stature, African American race, female gender, smoker, higher BMI, fewer years of formal
education, and higher levels of inflammatory markers. In each race- and gender- specific
group, participants who developed new-onset AF had lower mean baseline lung function
measure (FEV1 and FVC) than those who remained AF free at the end of study follow up
(Table 2).
Pulmonary function test and AF risk
The AF incidence rate decreased monotonically with higher FEV1 quartiles in each of the
four race-gender groups. The average incidence rates of AF per 1000 person years were
inversely related to quartiles of FEV1 and were (lowest to highest quartiles) 6.6, 3.8, 3.5 and
3.2 for white women; 13.7, 8.0, 7.8, and 6.2 for white men; 5.2, 3.2, 2.8, and 2.2 for black
women; and 7.5, 5.2, 2.7 and 2.7 for black men, after adjusting for age and sitting height and
height square (Table 3). Similar patterns were observed for FVC quartiles (Supplemental
Table 2). In analyses restricted to the never smokers group, significant inverse associations
between lung function and incident AF were observed (Table 4). The HRs comparing the
lowest to highest quartiles of FEV1 were of greater magnitude in African Americans (who
had lower absolute rates) than among Caucasians (p for interaction = 0.15). These HRs were
attenuated after additional adjustment for traditional CVD risk factors and systemic markers
of inflammation but remained statistically significant. Independent of age, sitting height and
smoking status, the hazards of incident AF increased monotonically and inversely by FEV1
quartiles (Figure 2). Kaplan-Meier survival curves also revealed a monotonic association
between FEV1 and incident AF (Figure 3). In a sub-group analysis restricted to those
without HF or/and CHD at baseline visit, the results did not change appreciably
(Supplemental Table 3). Further analysis restricted to those without airflow obstruction at
baseline showed a similar inverse association between FEV1 and AF incidence
(Supplemental Table 4). Although our primary analyses do not assume linearity, for
comparison with previous studies we provide an analysis based on the continuous variable
(Supplemental Table 5).
In sub-analyses, similar trend was observed for FVC quartiles; however, the inverse
association was not significant after further adjusting for CVD risk factors and systemic
markers of inflammation/hemostasis (Supplemental Table 2).
Since the associations between FEV1 and FVC with incident AF appear to be approximately
monotonic, models were fit using continuous lung function measures (Supplemental Table
5). Results are presented for 1 race- and gender- specific SD decreases. The results were
consistent with those from the quartile analyses. The cut points for quartile FEV1/FVC were
0.72, 0.86, and 0.97 for white women; 0.69, 0.74, 0.82 for white men; 0.74, 0.79, and 0.82
for black women; and 0.71, 0.76, and 0.81 for black men. For most race gender groups the
boundary of FEV1 over FVC quartile was around 0.70 and those with value lower than this
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had an almost log-linear increase in AF risk (Supplemental Figure 1 and Supplemental Table
2).
Airflow Obstruction and AF
In multivariable adjusted models, those with airflow obstruction (FEV1/FVC < 70%) had
higher AF incidence than those without, hazard ratio were 1.58 (1.29, 1.93) for white
women, 1.37 (1.17, 1.60) for white men, 1.10 (0.73, 1.67) for black women, and 1.69 (1.13,
2.55) for black men. Kaplan-Meier survival curves also suggested a monotonic association
between airflow obstruction and incident AF (Figure 4). Self-reported physician diagnosis of
emphysema or asthma was associated with incident AF among black men but not among
any other groups (Table 5). Additional adjustment for use of beta adrenergic agonists, anti-
cholinergics, and xanthines didn’t change the effect estimates or their confidence interval for
the association between FEV1 and AF, or between airflow obstruction and AF (data not
shown).
Discussion
In this large population-based, bi-racial, bi-gender cohort, a lower FEV1 was associated with
a higher AF incidence independent of several confounders during an average follow up of
17.5 years.. This inverse association was independent of smoking: it persisted after
adjustment for smoking status and cumulative amount smoked and was also seen among
never smokers. We found four prospective population-based studies that also evaluated the
association of lung function with the risk of AF 9–12. However, none of these above studies
conducted a stratified analysis by smoking status. Our results are consistent with the short
term follow up findings from both the Copenhagen City Heart Study 12, and the
Cardiovascular Health Study 10. We extend these results with a longer follow up of a
biracial cohort and establishing independence from smoking by examining never smokers
separately.
We also observed an association of incident AF with both self-reported physician diagnosis
of emphysema and spirometry-defined airflow obstruction. Our findings are consistent with
a cross-sectional study 27, where AF prevalence ratios increased with the severity of airflow
obstruction. Impaired lung function may increase the risk of AF through several potential
mechanisms. Ectopic beats that initiate AF are more likely to originate in the walls of the
pulmonary veins where they merge with atria 28. Though emphysematous changes primarily
affect right sided cardiac chambers, few recent studies have shown that moderate
emphysema is associated with left ventricular hypertrophy23, diastolic dysfunction25, 29,
narrower pulmonary vein diameter30, and structural/electrical abnormalities in pulmonary
vein area30. Impaired lung function could trigger ectopic beats by deterioration of gas
composition and pulmonary hypertension 31, resulting in elevated atrial pressure and alter
the electro-physiologic properties of atrial tissues, which in turn trigger AF 32. Fibrosis of
pulmonary veins 33 and stretching of pulmonary veins via increased intra-atrial pressure 34
may also play a role to initiate new-onset AF in individuals with airflow obstruction. The
above mechanisms remain speculative and needs further studies using animal models as well
among humans. AF ablation registries may help understand the above putative mechanisms.
Other potential pathways involve chronic systemic inflammation and endothelial
dysfunction that involves the cardiopulmonary system. The inverse associations between
lung function and incident AF were attenuated slightly after additional adjustment for
systemic markers of inflammation in our study. Considerable epidemiologic, clinical trial
and animal experimental evidence indicate that levels of systemic markers of inflammation
are higher in those with low lung volumes. In turn, an involvement of chronic systemic
inflammation in the pathogenesis of some chronic respiratory disease 35 and AF 32, 36 has
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also been reported. Higher serum concentrations of non-specific markers of inflammation
such as C-reactive protein and interleukin-6 have been observed in patients with
postoperative AF compared to the controls36–38. Recent studies suggested that elevated
white blood cell count 32, 39 and C-reactive protein levels 40 were associated with AF in
studies with both cross-sectional and longitudinal design. In addition, COPD was associated
with higher risk of pneumonia41, and pneumonia episodes and their severity have been
associated with higher AF incidence42. Those associations were independent of several
CVD risk factors, such as smoking, previous myocardial infarction or HF We observed
attenuation of the HR estimates after additional adjustment for baseline levels of
inflammatory markers. The present results could not be attributed to either HF or CHD,
although some of the potential mechanisms mentioned above may be associated with CHD
and HF. It could be argued that participants with HF have some reduction in lung function,
which could explain the association between FEV1 and AF. For instance, HF may
predispose to AF through increased atrial filling pressures and atrial dilation 43; and HF may
result in fibrosis and regional conduction abnormalities chronically, which in turn may
provide a substrate for AF initiation 30. Recently, a strong inverse association between
reduced lung function and HF has been demonstrated6. In our study the inverse association
of FEV1 with incidence of AF remained statistically significant after excluding participants
with either HF or CHD at baseline. Lastly, though, medications such as anti-cholinergics,
beta agonists, and oral methy-xanthines are potentially arrhythmogenic, their use at baseline
visit was low and their adjustment didn’t result in any appreciable change in the putative
relationship.
Our study has a number of strengths including a relatively large sample size and diverse
population, which enabled the estimation of precise incidence rates, stratified by race,
gender, and smoking status. In addition, the standardized protocol and the rigorous quality
assurance are key strengths. Furthermore, the availability of three decades of longitudinal
follow-up permitted complete follow-up (to time of death) on nearly all participants. The
prospective design reduces potential bias from recall, while the completeness of follow-up
and the annual review of all hospitalization reduce potential for missed or misclassified
outcomes.
A few limitations in this study should be considered. Although AF ascertainment in our
study was mostly based on hospital discharge codes, previous studies have shown that the
validity of AF ascertainment using hospitalizations is acceptable 15, 44, and the incidence of
AF in ARIC is similar to those in other studies with a validation of AF 45. Nevertheless,
because participants admitted for comorbid conditions including airflow obstruction may
increase propensity of AF detection, this may result in some lead time bias. The definition of
new cases of AF in this study could potentially exclude detection of new cases of
paroxysmal AF that might not have been detected by ECG or by hospital diagnosis.
However, individuals with an index AF event have a high rate of recurrence and conversion
to persistent AF 16. The associations were consistent when AF diagnosis was restricted to
diagnosis using study ECG only. Lastly, the possibility of residual confounding cannot be
excluded though the extent of potential bias is likely small given our detailed adjustment for
known confounders. In addition, as noted, we classified airflow obstruction based on
spirometry values without administration of bronchodilator.
Conclusion
Our findings indicate that reduced lung function is associated with a higher incidence of AF,
independent of race, gender, smoking, and several other CVD risk factors. Since AF may
cause high morbidity from stroke and is associated with increased mortality, our findings
suggest that more attention to AF in individuals with impaired lung function and airflow
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obstruction is warranted. If these findings are replicated in other cohorts, future studies of
the potential mechanisms underlying the observed association may provide other
opportunities for AF prevention.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Hazard ratio (HR, solid line) with 95% confidence intervals (CI, dotted lines)of atrial
fibrillation by forced expiratory volume (1s) (FEV1, 1a) and by Forced vital capacity (FVC,
1b), adjusted for sex, race, age (continuous), sitting height, and sitting height2. The curves
are plotted using restricted cubic splines with multiple knots.
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Estimated Hazard Ratio (95% confidence intervals) of incident atrial fibrillation for the
quartiles of forced expiratory volume (1s) for each gender- and race- specific group,
adjusted for age (continuous), sitting height, sitting height2, and smoking. Y axis is plotted
on a log scale.
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Kaplan-Meier atrial fibrillation free survival curves by gender and race specific quartiles
(Q1 - lowest quartile, Q4 - highest quartile) of forced expiratory volume (1s) i.e., FEV1.
Data are from the Atherosclerosis Risk in Communities Study (ARIC) baseline examination
(1987–89) in a subsample without prevalent atrial fibrillation and no missing information on
important covariates, followed up through 2008.
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Kaplan-Meier atrial fibrillation free survival curves by airflow obstruction defined by non-
bronchodilator spirometry data using Global Obstructive Lung Disease initiative criteria.
Data are from the Atherosclerosis Risk in Communities Study (ARIC) baseline examination
(1987–89) in a subsample without prevalent atrial fibrillation and no missing information on
important covariates, followed up through 2008.
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